Optimizing Outcomes with Oral Therapies in Plaque Psoriasis - Episode 8
Head-to-head TYK2 data show that agents within the same mechanistic class may differ meaningfully in speed, depth of clearance, and target selectivity.
In this episode, ‘Next-Generation TYK2 Inhibitors and Speed of Response in PsO,’ the expert dermatology panel explores how quickly oral therapies can improve plaque psoriasis and how newer TYK2 inhibitors may differ despite sharing the same therapeutic target. Faculty note that earlier oral agents such as deucravacitinib can require several months to approach maximal response, making treatment expectations and patient counseling particularly important.
The discussion highlights the LATITUDE head-to-head comparison of zasocitinib and deucravacitinib. The panel describes greater and earlier skin-clearance responses with zasocitinib and emphasizes the significance of complete skin clearance as a clinical trial endpoint. These findings illustrate that drugs targeting the same pathway are not necessarily interchangeable in their clinical performance.
Faculty also discuss envudeucitinib and the broader evolution of next-generation TYK2 inhibition, noting increasingly deep PASI responses with newer investigational agents. Importantly, the panel points out that symptomatic benefit may occur before visible skin clearance. Improvements in itch and quality of life with potent TYK2 inhibition were observed earlier than PASI 90 responses, highlighting the value of patient-reported outcomes in evaluating early treatment benefit.
The episode concludes with a mechanistic comparison of zasocitinib and deucravacitinib, including differences in TYK2 selectivity and duration of pathway inhibition that may contribute to observed differences in efficacy.
The next episode in this series, ‘Safety and Tolerability Profiles of Oral Agents for PsO,’ features the panelists examining class-specific adverse effects and safety considerations across PDE4, TYK2, and oral IL-23–targeted treatments.